| Dr Sheila Ramgopal, MD | |
|
845 Helen Dr, Lebanon, PA 17042-7493 | |
| (717) 273-8835 | |
| (717) 202-0100 |
| Full Name | Dr Sheila Ramgopal |
|---|---|
| Gender | Female |
| Speciality | Obstetrics & Gynecology |
| Location | 845 Helen Dr, Lebanon, Pennsylvania |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1932333416 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | FR2881197 (Pennsylvania) | Secondary |
| 207V00000X | Obstetrics & Gynecology | MD444235 (Pennsylvania) | Primary |
| Entity Name | Upmc Community Medicine Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558976092 PECOS PAC ID: 2062318975 Enrollment ID: O20040217000388 |
News Archive
After studies appeared showing that treating menopausal complaints with estrogen entailed not wholly positive health effects, the prescription of such preparations declined.
Raptor Pharmaceutical Corp., today announced it has completed enrollment in its Phase 3 clinical trial of its proprietary delayed-release oral formulation of cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis").
On the one-year anniversary of the U.N. High-Level Meeting on Non-Communicable Diseases (NCDs), two blogs examine what has happened since. In the Center for Global Development's (CGD) "Global Health Policy" blog, Victoria Fan, a research fellow at the center, and Laura Khan of Princeton University ask, "[W]here has the attention and commitment to NCDs gone?" They say "subsequent attention and action after the NCD Summit last year has been paltry," and they explore some reasons why this might be the case.
More intensive management of high blood pressure, below a commonly recommended blood pressure target, significantly reduces rates of cardiovascular disease, and lowers risk of death in a group of adults 50 years and older with high blood pressure, a National Institutes of Health study involving UT Southwestern Medical Center researchers shows.
A new family of molecules that kill cancer cells and protect healthy cells could be used to treat a number of different cancers, including cervical, breast, ovarian and lung cancers. Research published in EBioMedicine shows that as well as targeting and killing cancer cells, the molecules generate a protective effect against toxic chemicals in healthy cells.
› Verified 5 days ago
| Entity Name | Wellspan Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750480299 PECOS PAC ID: 1951213115 Enrollment ID: O20040220000815 |
News Archive
After studies appeared showing that treating menopausal complaints with estrogen entailed not wholly positive health effects, the prescription of such preparations declined.
Raptor Pharmaceutical Corp., today announced it has completed enrollment in its Phase 3 clinical trial of its proprietary delayed-release oral formulation of cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis").
On the one-year anniversary of the U.N. High-Level Meeting on Non-Communicable Diseases (NCDs), two blogs examine what has happened since. In the Center for Global Development's (CGD) "Global Health Policy" blog, Victoria Fan, a research fellow at the center, and Laura Khan of Princeton University ask, "[W]here has the attention and commitment to NCDs gone?" They say "subsequent attention and action after the NCD Summit last year has been paltry," and they explore some reasons why this might be the case.
More intensive management of high blood pressure, below a commonly recommended blood pressure target, significantly reduces rates of cardiovascular disease, and lowers risk of death in a group of adults 50 years and older with high blood pressure, a National Institutes of Health study involving UT Southwestern Medical Center researchers shows.
A new family of molecules that kill cancer cells and protect healthy cells could be used to treat a number of different cancers, including cervical, breast, ovarian and lung cancers. Research published in EBioMedicine shows that as well as targeting and killing cancer cells, the molecules generate a protective effect against toxic chemicals in healthy cells.
› Verified 5 days ago
| Entity Name | University Of Pittsburgh Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619935004 PECOS PAC ID: 8729990239 Enrollment ID: O20040308000883 |
News Archive
After studies appeared showing that treating menopausal complaints with estrogen entailed not wholly positive health effects, the prescription of such preparations declined.
Raptor Pharmaceutical Corp., today announced it has completed enrollment in its Phase 3 clinical trial of its proprietary delayed-release oral formulation of cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis").
On the one-year anniversary of the U.N. High-Level Meeting on Non-Communicable Diseases (NCDs), two blogs examine what has happened since. In the Center for Global Development's (CGD) "Global Health Policy" blog, Victoria Fan, a research fellow at the center, and Laura Khan of Princeton University ask, "[W]here has the attention and commitment to NCDs gone?" They say "subsequent attention and action after the NCD Summit last year has been paltry," and they explore some reasons why this might be the case.
More intensive management of high blood pressure, below a commonly recommended blood pressure target, significantly reduces rates of cardiovascular disease, and lowers risk of death in a group of adults 50 years and older with high blood pressure, a National Institutes of Health study involving UT Southwestern Medical Center researchers shows.
A new family of molecules that kill cancer cells and protect healthy cells could be used to treat a number of different cancers, including cervical, breast, ovarian and lung cancers. Research published in EBioMedicine shows that as well as targeting and killing cancer cells, the molecules generate a protective effect against toxic chemicals in healthy cells.
› Verified 5 days ago
| Entity Name | Obhg Pennsylvania Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184124109 PECOS PAC ID: 1355684507 Enrollment ID: O20190510000946 |
News Archive
After studies appeared showing that treating menopausal complaints with estrogen entailed not wholly positive health effects, the prescription of such preparations declined.
Raptor Pharmaceutical Corp., today announced it has completed enrollment in its Phase 3 clinical trial of its proprietary delayed-release oral formulation of cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis").
On the one-year anniversary of the U.N. High-Level Meeting on Non-Communicable Diseases (NCDs), two blogs examine what has happened since. In the Center for Global Development's (CGD) "Global Health Policy" blog, Victoria Fan, a research fellow at the center, and Laura Khan of Princeton University ask, "[W]here has the attention and commitment to NCDs gone?" They say "subsequent attention and action after the NCD Summit last year has been paltry," and they explore some reasons why this might be the case.
More intensive management of high blood pressure, below a commonly recommended blood pressure target, significantly reduces rates of cardiovascular disease, and lowers risk of death in a group of adults 50 years and older with high blood pressure, a National Institutes of Health study involving UT Southwestern Medical Center researchers shows.
A new family of molecules that kill cancer cells and protect healthy cells could be used to treat a number of different cancers, including cervical, breast, ovarian and lung cancers. Research published in EBioMedicine shows that as well as targeting and killing cancer cells, the molecules generate a protective effect against toxic chemicals in healthy cells.
› Verified 5 days ago
| Entity Name | Reprochoice Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326073933 PECOS PAC ID: 6305178245 Enrollment ID: O20191028000220 |
News Archive
After studies appeared showing that treating menopausal complaints with estrogen entailed not wholly positive health effects, the prescription of such preparations declined.
Raptor Pharmaceutical Corp., today announced it has completed enrollment in its Phase 3 clinical trial of its proprietary delayed-release oral formulation of cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis").
On the one-year anniversary of the U.N. High-Level Meeting on Non-Communicable Diseases (NCDs), two blogs examine what has happened since. In the Center for Global Development's (CGD) "Global Health Policy" blog, Victoria Fan, a research fellow at the center, and Laura Khan of Princeton University ask, "[W]here has the attention and commitment to NCDs gone?" They say "subsequent attention and action after the NCD Summit last year has been paltry," and they explore some reasons why this might be the case.
More intensive management of high blood pressure, below a commonly recommended blood pressure target, significantly reduces rates of cardiovascular disease, and lowers risk of death in a group of adults 50 years and older with high blood pressure, a National Institutes of Health study involving UT Southwestern Medical Center researchers shows.
A new family of molecules that kill cancer cells and protect healthy cells could be used to treat a number of different cancers, including cervical, breast, ovarian and lung cancers. Research published in EBioMedicine shows that as well as targeting and killing cancer cells, the molecules generate a protective effect against toxic chemicals in healthy cells.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sheila Ramgopal, MD 5910 Kirkwood St, Pittsburgh, PA 15206-3048 Ph: (412) 661-8811 | Dr Sheila Ramgopal, MD 845 Helen Dr, Lebanon, PA 17042-7493 Ph: (717) 273-8835 |
News Archive
After studies appeared showing that treating menopausal complaints with estrogen entailed not wholly positive health effects, the prescription of such preparations declined.
Raptor Pharmaceutical Corp., today announced it has completed enrollment in its Phase 3 clinical trial of its proprietary delayed-release oral formulation of cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis").
On the one-year anniversary of the U.N. High-Level Meeting on Non-Communicable Diseases (NCDs), two blogs examine what has happened since. In the Center for Global Development's (CGD) "Global Health Policy" blog, Victoria Fan, a research fellow at the center, and Laura Khan of Princeton University ask, "[W]here has the attention and commitment to NCDs gone?" They say "subsequent attention and action after the NCD Summit last year has been paltry," and they explore some reasons why this might be the case.
More intensive management of high blood pressure, below a commonly recommended blood pressure target, significantly reduces rates of cardiovascular disease, and lowers risk of death in a group of adults 50 years and older with high blood pressure, a National Institutes of Health study involving UT Southwestern Medical Center researchers shows.
A new family of molecules that kill cancer cells and protect healthy cells could be used to treat a number of different cancers, including cervical, breast, ovarian and lung cancers. Research published in EBioMedicine shows that as well as targeting and killing cancer cells, the molecules generate a protective effect against toxic chemicals in healthy cells.
› Verified 5 days ago
Dr. Daniel P Rollo, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 300 Willow St, Lebanon, PA 17046 Phone: 717-273-8835 Fax: 717-273-0728 | |
Dr. Maryanne T. Mclaughlin, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 845 Helen Dr, Lebanon, PA 17042 Phone: 717-273-8835 Fax: 717-202-0100 | |
Dr. Roger A. Hine, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 845 Helen Dr, Lebanon, PA 17042 Phone: 717-273-8835 Fax: 717-202-0100 | |
Dennis J Easter, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 845 Helen Dr, Lebanon, PA 17042 Phone: 717-273-8835 Fax: 717-202-0100 | |
Nathan Adam Keller, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 845 Helen Dr, Lebanon, PA 17042 Phone: 717-273-8835 Fax: 717-202-0100 | |
James A Nicholson, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 30 N 4th St Fl 2, Lebanon, PA 17046 Phone: 717-274-0474 Fax: 717-270-2374 | |
Dr. Raliat Oluwafunke Bashua, Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 845 Helen Dr, Lebanon, PA 17042 Phone: 717-273-8835 Fax: 717-202-0100 |